Inspiratory muscle trainer (e.g. The Breather)
What studies of Inspiratory muscle trainer (e.g. The Breather) found
At a glance, by condition
Long COVID: D Little or no difference
Based on the strongest evidence, randomised trials and the randomised trial (very low certainty): 3 of 4 findings are D.
5 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with Inspiratory muscle trainer (e.g. The Breather) for long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Inspiratory muscle trainer (e.g. The Breather) · Long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Breathlessness4 studies · 114 people used Inspiratory muscle trainer (e.g. The Breather) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (182 in all); the studies disagree.
Randomised trials4 studies · 182 people with results
Breathlessness improved more than in the comparison group.
The evidence is very uncertain about the effect of inspiratory muscle trainer (e.g. The Breather) on breathlessness in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (182 in all)
- The studies disagree
See the 4 studies
-
- People in the study
- 59 randomised
- Dose
- 6 sets of 6 maximally deep breaths exceeding the threshold value of pressure from 45–55% to 70–80% of PImax; duration of 15–20 min, during each ambulatory training session
- Outcome
- PImax maximum inspiratory pressure
- Effect
- worse (not tested)
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 64 randomised
- Dose
- 40min/day, 3 times/wk
- Outcome
- MIP (cmH2O) (% pred) maximal static inspiratory pressure
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 30 randomised · 18 started
- Dose
- one session of 30 breaths in the morning and one session of 30 breaths in the evening, 6 weeks
- Outcome
- Sniff nasal pressure, cm H2O sniff nasal inspiratory pressure
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
-
- People in the study
- 30 randomised · 29 analysed
- Dose
- 90 breaths per session, divided into three sets, three times per week
- Outcome
- PEmax maximal expiratory pressure
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Fatigue1 study · 17 people used Inspiratory muscle trainer (e.g. The Breather) Uncertain –
Why this grade: Uncertain, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (80 in all); helped less than ct, an active treatment; not a sign of harm.
The randomised trial80 randomised · 8-wk · 1 set of 30 repetitions [62.5 ± 4.6% of the PIM (maximum inspiratory pressure)], twice a day, every day of the week
Fatigue improved less than with the comparison treatment.
Inspiratory muscle trainer (e.g. The Breather) helped fatigue less than ct in the one comparison. Uncertain · very low certainty –
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (80 in all)
- Helped less than ct, an active treatment; not a sign of harm
See the 1 study
-
- People in the study
- 80 randomised
- Dose
- 1 set of 30 repetitions [62.5 ± 4.6% of the PIM (maximum inspiratory pressure)], twice a day, every day of the week
- Outcome
- Fatigue (FFS and CFS-Linkert) and depression (PHQ-9)
- Effect
- worse
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Daily life and health overall
Daily functioning4 studies · 174 people used Inspiratory muscle trainer (e.g. The Breather) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 321 people in all; a small benefit can't be ruled out; the studies disagree.
Randomised trials4 studies · 321 people with results
No clear difference in daily functioning.
The evidence is very uncertain about the effect of inspiratory muscle trainer (e.g. The Breather) on daily functioning in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- 321 people in all; a small benefit can't be ruled out
- The studies disagree
See the 4 studies
-
- People in the study
- 64 randomised
- Dose
- 40min/day, 3 times/wk
- Outcome
- Exercise tolerance (CPET) peak VO2 cardiopulmonary exercise test
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 80 randomised
- Dose
- 1 set of 30 repetitions [62.5 ± 4.6% of the PIM (maximum inspiratory pressure)], twice a day, every day of the week
- Outcome
- dominant hand grip strength
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
-
Inspiratory muscle training enhances recovery post-COVID-19: a randomised controlled trial. (2022)
- People in the study
- 281 randomised · 148 analysed
- Dose
- three unsupervised IMT sessions per week, on nonconsecutive days, for 8 weeks; >80% SMIP; up to six blocks of six inspirations, three unsupervised sessions per week, on nonconsecutive days, for 8 weeks
- Outcome
- Sedentary time (min)
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- High
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 30 randomised · 29 analysed
- Dose
- 90 breaths per session, divided into three sets, three times per week
- Outcome
- TSL time to stand and sit
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Quality of life2 studies · 143 people used Inspiratory muscle trainer (e.g. The Breather) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 212 people in all; a small benefit can't be ruled out.
Randomised trials2 studies · 212 people with results
No clear difference in quality of life.
The evidence is very uncertain about the effect of inspiratory muscle trainer (e.g. The Breather) on quality of life in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- 212 people in all; a small benefit can't be ruled out
See the 2 studies
-
- People in the study
- 64 randomised
- Dose
- 40min/day, 3 times/wk
- Outcome
- Health-related quality of life (HRQoL) health-related quality of life
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
Inspiratory muscle training enhances recovery post-COVID-19: a randomised controlled trial. (2022)
- People in the study
- 281 randomised · 148 analysed
- Dose
- three unsupervised IMT sessions per week, on nonconsecutive days, for 8 weeks; >80% SMIP; up to six blocks of six inspirations, three unsupervised sessions per week, on nonconsecutive days, for 8 weeks
- Outcome
- K-BILD total score King's Brief Interstitial Lung Disease questionnaire
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- High
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Overall symptoms1 study · 17 people used Inspiratory muscle trainer (e.g. The Breather) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 80 people found no clear difference; a small benefit can't be ruled out.
The randomised trial80 randomised · 8-wk · 1 set of 30 repetitions [62.5 ± 4.6% of the PIM (maximum inspiratory pressure)], twice a day, every day of the week
No clear difference in overall symptoms.
The evidence is very uncertain about the effect of inspiratory muscle trainer (e.g. The Breather) on overall symptoms in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 80 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 80 randomised
- Dose
- 1 set of 30 repetitions [62.5 ± 4.6% of the PIM (maximum inspiratory pressure)], twice a day, every day of the week
- Outcome
- other symptom prevalence, including headache, brain fog, or neurocognitive manifestations
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Side effects
Stopping because of side effects2 studies
Two participants (12.5%) discontinued the IMT in the first week due to discomfort experienced during training.
FEASIBILITY OF INSPIRATORY MUSCLE TRAINING FOR PATIENTS WITH PERSISTENT DYSPNOEA AFTER COVID-19 INFECTION: A PILOT STUDY. (2023)Among 13 patients assigned to the IMT group, 12 completed all weekly physiotherapist visits and one interrupted their weekly physiotherapist visit for 2 weeks due to SARS-CoV-2 reinfection.
Effect of a home-based inspiratory muscle training programme on functional capacity in postdischarged patients with long COVID: the InsCOVID trial. (2022)
Side effects studies reported1 kind
| Side effect | Studies that reported it |
|---|---|
| Headache | 1 study |
All papers
- Effectiveness of comprehensive rehabilitation for functional recovery and symptom reduction in long COVID: results from a six‑month randomised controlled trial.2026 · placebo trial · 123 randomised · 109 started · 75 analysed
Summary
This randomised controlled trial examined a six-week comprehensive rehabilitation programme for patients with long COVID at the Department of Rehabilitation, Medical University of Bialystok, Poland. Of 123 individuals, 109 were randomised to an intervention or control group; 75 patients completed the programme and were analysed. Both groups followed an identical protocol including aerobic training, respiratory exercises, strength and general fitness training, stretching, and respiratory resistance training with a respiratory muscle trainer. The intervention group used the trainer at individually prescribed workloads, starting at 45–55% in Week 1 and increasing to 70–80% by Week 6; the control group used the same device under unloaded (sham) conditions. The programme consisted of 18 supervised sessions, 60–90 min each, three times weekly. Outcomes included 6MWD, PImax, PEmax, spirometry, chest wall mobility, diaphragmatic ultrasound, voice and speech measures, and symptom scales. The paper reports that the intervention and control groups were merged because no significant differences were observed between them in the investigated parameters except for spirometric values (FEV1, FVC, VCMAX, and PEF). It reports improvements from baseline to post-intervention and six months in 6MWD, PImax, PEmax, spirometry indices, chest expansion, DTF, dyspnoea, and some symptoms. It also reports a marginal reduction in PImax and PEmax values, alongside increased reports of cough and headaches during follow-up, and states no significant health deterioration was observed at 6-month follow-up. Withdrawals and reasons for withdrawal were not reported. The authors state limitations including a limited number of randomised trials and methodological challenges.
- Effect of respiratory rehabilitation on quality of life in individuals with post-COVID-19 symptoms: A randomised controlled trial.2025 · placebo trial · 64 randomised
- Effects of Pulmonary Rehabilitation on Respiratory Function and Thickness of the Diaphragm in Patients with Post-COVID-19 Syndrome: A Randomized Clinical Trial.2024 · placebo trial · 59 randomised
Summary
This double-blind randomized trial assessed a six-week outpatient rehabilitation programme in 59 patients (37 women and 22 men) with post-COVID-19 syndrome at the Department of Rehabilitation of the Medical University of Bialystok, Poland. Both groups completed the same six-week comprehensive exercise training programme, including aerobic, respiratory, resistance, fitness and stretching exercises plus education; the study group also used a respiratory muscle trainer (Philips Respironics Threshold IMT) during each ambulatory session, while the control group performed placebo IMT. Outcomes included respiratory muscle strength, chest wall expansion, spirometry and diaphragm ultrasonography before and after six weeks. Respiratory muscle strength improved in both groups (p < 0.001). Chest circumference increased in the study group (p < 0.001). Spirometry improved in both groups, with the study group showing 8.02% in FEV1 (p < 0.001), 13.24% in FVC EX (p < 0.001) and 9.67% in PEF (p < 0.001). Diaphragm thickness during maximum inhalation increased in both groups. The majority of analyzed functional parameters, including diaphragm changes, showed no significant differences post-rehabilitation. The authors report a higher average increase in PImax in the control group than the study group. During rehabilitation, no significant or serious adverse events were reported; four respiratory infections lasting longer than two weeks, two mild respiratory infections, 14 patients with increased fatigue and dyspnea at training start, 3 with minor hip discomfort and 2 with knee discomfort were reported. The paper also states that after randomization not all participants qualified for completion.
- Effect of Inspiratory Muscle Training on Aerosol Deposition and Pulmonary Perfusion in Post-COVID-19 Syndrome: A Gamma Scintigraphy Study.2026 · randomised trial · 19 randomised
Summary
This randomized controlled clinical trial involved 19 participants with post-COVID-19 syndrome, divided into an inspiratory muscle training group (n = 10) and a control group (n = 9). The training group performed training with a load adjusted to 50% of maximal inspiratory pressure, while the control group used a device without resistance, over 8 weeks. Aerosol deposition and pulmonary perfusion were evaluated by gamma scintigraphy before and after the intervention. After 8 weeks, the training group showed a significant increase in total lung activity for both aerosol deposition (p = 0.028) and perfusion (p = 0.013). In the right lung, activity increased significantly for aerosol deposition (p = 0.005) and perfusion (p = 0.005). In the left lung, significant increases were also observed for perfusion (p = 0.007). No significant increases were observed in the control group. In the between-group analysis, the training group showed higher activity in both lungs combined and separately, compared with controls, for aerosol deposition (all p < 0.05) and in the right lung for perfusion (p = 0.010). Harms, withdrawals and the number of participants analysed were not reported. The abstract reports no limitations.
- Exercise-Based Rehabilitation in Severe COVID-19 Survivors with Long COVID: A Randomized Controlled Pilot Study.2026 · randomised trial · 30 randomised · 29 analysed
Summary
Thirty survivors of severe COVID-19 were randomised to multicomponent exercise (GEm) or multicomponent exercise plus inspiratory muscle training (GEmTMI); 29 were analysed (GEm n = 15, GEmTMI n = 14). Sessions were three times per week for 40–60 min for six weeks, and outcomes were collected at baseline and after six weeks. Quality of life, physical activity level, functional status and physical capacity were measured. After rehabilitation, the total sample showed significant improvements across all outcomes, including quality of life (SF-36), functional capacity (PCFS), physical activity level (IPAQ), respiratory muscle strength and additional functional tests. Between-group comparisons showed a significant difference in the Physical Activity Index (IPAQ) after the intervention (p = 0.002) and in the 6 min walk test at baseline (p = 0.043). For assessed parameters in Table 5, both groups improved and no significant between-group differences were observed. No adverse events were reported during the program; SpO2 remained above 90% in all participants. One patient was excluded due to absences related to transportation difficulties. The authors state limitations including a small sample size and the absence of a control group, and note that improvements may partly reflect natural recovery.
- Beyond the pandemic : health outcomes and targeted, individualised rehabilitation in post-COVID-19 condition2026 · randomised trial · 44 randomised
- Potential Diaphragm Muscle Weakness-related Dyspnea Persists 2 Years after COVID-19 and Could Be Improved by Inspiratory Muscle Training: Results of an Observational and an Interventional Clinical Trial.2024 · randomised trial · 30 randomised · 18 started
- Effects of a concurrent training, respiratory muscle exercise, and self-management recommendations on recovery from post-COVID-19 conditions: the RECOVE trial.2023 · randomised trial · 80 randomised
Summary
To determine the effects of exercise, respiratory muscle training, and WHO self-management recommendations in nonhospitalized adults with a post-COVID-19 condition, the RECOVE trial randomly assigned eighty adults to four 8-wk groups: concurrent training (CT, n = 20), inspiratory muscle training (RM, n = 17), both (CTRM, n = 23), or control following the WHO leaflet (CON, n = 20). Participants were recruited through advertisements on social media or via general practitioners. Outcomes included estimated V̇o2max, lower and upper body strength, hand grip strength, symptom number, and patient-reported outcomes. No significant between-group difference was detected in estimated V̇o2max; individual improvements were 7.5% in CT and 7.8% in CTRM. Lower body strength improved in CT and CTRM (14.5%–32.6%) compared with RM and CON (−0.3% to 11.3%). Symptoms decreased on average by −3 for CT and CTMR and −1 for RM and CON; CT and CTRM had a significant symptom reduction versus RM and CON. Dyspnea, fatigue, and anxiety improved in favor of CT and CTRM (Δ −50 to 13%). Fatigue and depression improved in concurrent training groups (P = 0.007–0.039). No significant between-group differences were found for mMRC, GAD-7, PCFS, or SF-12 PA and MH, and no inter- or intragroup interactions for hand grip. The paper states no adverse event occurred during training sessions; three patients dropped out for reasons unrelated to symptom worsening. The authors state limitations include sample size/participant characteristics and lack of post-intervention follow-up.
- Inspiratory muscle training enhances recovery post-COVID-19: a randomised controlled trial.2022 · randomised trial · 281 randomised · 148 analysed
Summary
This two-arm randomised controlled trial asked whether 8 weeks of inspiratory muscle training (IMT) would help adults recovering from self-reported COVID-19 with prolonged breathlessness. 281 adults (age 46.6±12.2 years; 88% female; 9.0±4.2 months post-acute infection) were randomised 4:1 to unsupervised home IMT or a usual care waitlist control. 148 participants completed post-intervention testing and were included in the intention-to-treat analysis (IMT n=111; controls n=37); 124 were in the per-protocol population (IMT n=87; controls n=37). The primary outcome was K-BILD total score. In the intention-to-treat analysis there was no between-group difference in K-BILD total score post-intervention (control 59.5±12.4; IMT 58.2±12.3; p<0.05). In the per-protocol population, K-BILD total score was higher in the IMT group than control post-intervention (67.8±14.4 versus 59.8±12.6). TDI breathlessness favoured IMT in the intention-to-treat analysis (2.0±2.0 versus 0.9±1.7; p=0.005) and per-protocol analysis (2.1±0.2 versus 0.9±0.3; p=0.005). IMT improved MIP, SMIP, FIT and estimated V′O2max. Withdrawal between recruitment and enrolment (n=57) was mostly associated with IMT device manufacturing delays; no reason was provided for subsequent withdrawals. Side effects were not reported. The authors state limitations include unconfirmed SARS-CoV-2 in many participants, a higher proportion of females, no sham IMT and inability to contact many who withdrew.
- Effect of a home-based inspiratory muscle training programme on functional capacity in postdischarged patients with long COVID: the InsCOVID trial.2022 · randomised trial · 26 randomised
Summary
This single-centre, blinded assessor randomised controlled trial assessed a 12-week home-based inspiratory muscle training (IMT) programme in 26 adults with long COVID after admission for SARS-CoV-2 pneumonia. Participants were randomised to IMT (13) or usual care alone (13). The IMT arm trained at home twice daily for 20 min each session at 25%–30% of measured maximal inspiratory pressure using a threshold inspiratory muscle trainer; usual care received no intervention. The primary endpoint was change in peak oxygen consumption (peakVO2); secondary endpoints included quality of life, ventilatory efficiency and chronotropic response. At 3 months, mean peakVO2 was 22.2 mL/kg/min with IMT versus 17.8 mL/kg/min with usual care (Δ+4.46 mL/kg/min, 95% CI 3.10 to 5.81; p<0.001). Within-group peakVO2 increased by 3.4 mL/kg/min in the IMT group and decreased by −1.09 mL/kg/min in usual care. pp-peakVO2 was 89.1% versus 71.1% (Δ+18.03%). VE/VCO2 slope did not significantly differ (Δ−1.92, 95% CI −4.69 to 0.85; p=0.165). CIx was 0.75 versus 0.62 (Δ+0.13; p=0.046). Usual activities changed by −0.31 and anxiety/depression by −0.53; visual analogue scale changed by 21.1. Mobility, self-care and pain/discomfort were non-significant. Maximal inspiratory pressure improved by +79.4 cmH2O with IMT and +17.3 cmH2O with usual care (p=0.075). No adverse effects were reported; one IMT patient interrupted weekly physiotherapist visits for 2 weeks due to SARS-CoV-2 reinfection.
- Effects of an inpatient rehabilitation programme on functional capacity, quality of life and psychological distress in patients with post covid-19 condition: an observational study.2023 · compared with another group · 779 in the study
- Inspiratory and Expiratory Muscle Strength Training for Persistent Dyspnea in Post-COVID-19.2025 · no comparison group
- FEASIBILITY OF INSPIRATORY MUSCLE TRAINING FOR PATIENTS WITH PERSISTENT DYSPNOEA AFTER COVID-19 INFECTION: A PILOT STUDY.2023 · no comparison group · 16 in the study · 14 with outcome data
Summary
This mixed-methods pilot study asked whether inspiratory muscle training (IMT) could be delivered as part of physical therapy for patients with persistent dyspnoea after COVID-19. Sixteen patients received the intervention; 9 patients and 2 physical therapists took part in interviews. Patients performed daily home IMT with 30 inhalations against a pre-set resistance for 6 weeks, plus additional weekly physical therapy. No comparison group was reported. Feasibility covered acceptability, safety, adherence and patient- and professional experience; maximal inspiratory pressure (MIP) was secondary. Participants completed 495 out of a potential 672 sessions, adherence 73.7%. Protocol deviations occurred in 29.7% of performed sessions; 3 (18.8%) performed IMT more than once a day and 7 (43.8%) could not perform 30 repetitions in a single set. MIP was median 84.7% (34%) of predicted at baseline and 111.3% (66%) 6 weeks later in 14 patients. No adverse events related to IMT were observed. Two participants (12.5%) discontinued in the first week due to discomfort during training; the abstract says 2 dropped out before initiating training. Qualitative analysis identified barriers ‘Getting acquainted with the training material’ and ‘Finding the right schedule’, and facilitators ‘Support from physical therapists’ and ‘Experiencing improvements’. The authors state limitations include retrospective feasibility data and missing contextual information.
- Perceptions of inspiratory muscle training in adults recovering from COVID-19.2022 · no comparison group · 48 in the study · 33 with outcome data
Summary
This qualitative description study explored how adults recovering from COVID-19 experienced an eight-week inspiratory muscle training (IMT) rehabilitation programme. Forty-eight adults who were 6–11 months post-COVID-19 infection were recruited from a larger randomised controlled trial sample; 33 attended both pre- and post-IMT interviews. Participants used a resistive breathing device for three sessions per week for eight weeks, with each session consisting of up to six sets of six breaths. There was no comparison group. Individual semi-structured interviews before and after the intervention examined expectations and perceptions of IMT and its impact on recovery. The authors report that IMT helped many to feel proactive in managing symptoms and was associated with perceived improvements in respiratory symptoms, exercise and work capacity, and daily functioning. Some participants reported slight improvements, some reported no change, and some continued to experience fatigue and post-exertional symptom exacerbation. Harms described include exacerbations of symptoms during the intervention that hindered ability to complete training, discomfort, initial worsening of symptoms, and pains and tiredness after training; counts were not reported. Device and app problems were also described. The authors state limitations including potential self-selection bias, a predominantly female sample, and that a confirmed positive test was not required.
- Experiences of Inspiratory Muscle Training and Physical Exercise in Adults with Post-COVID-19 Condition and Inspiratory Muscle Weakness: A Qualitative Study.2026 · combination: given with other treatments · 12 in the study
Summary
This qualitative descriptive study interviewed 12 of 16 eligible adults with post-COVID-19 condition and inspiratory muscle weakness who had completed the intervention group of a preceding randomized controlled trial. Participants were recruited from a specialized post-COVID outpatient clinic at Karolinska University Hospital in Stockholm, Sweden. They had received an eight-week individualized intervention combining twice-daily inspiratory muscle training using a handheld device with twice-weekly physical exercise, with weekly physiotherapist follow-ups. This qualitative study had no comparison group; interviews were held a median of 46 days after RCT completion (Q1–Q3: 28–109). Participants described varying expectations, perceiving the intervention as a meaningful opportunity for self-directed action, and reported learning, gradual progression, and individual adjustments. They described physical and emotional strain, symptom-related uncertainty, and practical challenges. Professional support and regular, flexible follow-up were perceived to support continued engagement. Perceived outcomes ranged from partial improvements and renewed trust in bodies to uncertainty, no perceived change, or setbacks. Reported experiences included dizziness and nausea during IMT, and heaviness, muscle soreness, fatigue, and elevated heart rate during physical exercise; some described worsening of existing symptoms, new health problems, or deterioration. Four eligible individuals did not participate.
- Effects of high-definition transcranial direct current stimulation combined with inspiratory muscle training for treating respiratory sequelae of long COVID: A case series.2024 · combination: given with other treatments · 6 in the study
Summary
This case series treated six adults, four women and two men aged 29 to 71, who had breathing problems after COVID (long COVID). Each received high-definition transcranial direct current stimulation (HD-tDCS, a mild electrical current to the brain through the scalp) together with inspiratory muscle training, twice a week for 5 weeks. Lung function and breathing-muscle strength were measured at the start and after 5 weeks. The abstract gives no measured results and no side effects; the authors suggest that HD-tDCS may add to the effects of the muscle training. There was no comparison group.
- The Impact of Pulmonary Rehabilitation in Patients with Post-COVID-19 Syndrome: A Systematic Review.2026 · systematic review
Summary
This systematic review examined pulmonary rehabilitation for adults with post-COVID-19 syndrome. The authors searched PubMed, Embase and the Cochrane Central Register of Controlled Trials from January 2021 to January 2026, with the last search on 31 January 2026, and included 20 randomised controlled trials involving 2101 adult patients. Included trials compared pulmonary rehabilitation with in-hospital rehabilitation, telerehabilitation, standard care, educational counselling or sham devices, and assessed exercise capacity, pulmonary function, respiratory and peripheral muscle strength, quality of life, dyspnea, fatigue, anxiety and depression. Findings across the included trials were mixed. Some trials reported improvements in exercise capacity, such as one trial with a rehabilitation-group increase of +47.7 m on the 6MWT while the control group decreased by 14.2 m. Other trials reported no significant between-group differences for VO2max, quality of life, anxiety, depression or dyspnea. Trials comparing in-hospital rehabilitation with telerehabilitation generally reported improvements in both groups without significant between-group differences, except one trial reported a fatigue advantage for in-hospital rehabilitation. The extracted data include no side-effect counts or withdrawal numbers. The authors state that only half of the included trials had low risk of bias and note short-term outcomes, small samples, heterogeneous protocols, English-only inclusion, and no quantitative meta-analysis or GRADE assessment.
- Systematic Review of Randomized Clinical Trials for the Treatment of Long COVID Syndrome.2026 · systematic review
Summary
This systematic review asked whether treatments for long COVID improve outcomes. It searched MEDLINE through PubMed from 2020 to August 2024 and included 43 randomized clinical trials of people with long COVID. The trials compared interventions with control groups or other treatments and reported a primary outcome. Treatments included nutraceuticals, respiratory muscle training, supervised exercise or pacing, brain stimulation, and medications. Outcomes included symptoms, exercise capacity, Vo2 max, fatigue, cognitive functions, inspiratory pressure, pain, and olfactory and gustatory function. The review reports that all studies testing supervised exercises improved the primary outcome except for one; all but one brain stimulation study improved the primary outcome; and only 2 studies using medications improved the primary outcome. Nirmatrelvir/ritonavir did not improve symptoms; donepezil and lithium did not improve their primary outcomes; thermal water inhalation and a metabolic modulator did not improve the primary outcome. Creatine improved fatigue; vitamin C improved exercise capacity; inspiratory muscle training improved symptoms, exercise capacity and inspiratory pressure. Reported harms included 33% with adverse events (dry mouth) with amantadine, 16% nausea with creatine, 17%–37% adverse events with TMS, two to four percent TMS discontinuation, and 8% inspiratory muscle training discontinuation. The authors state the evidence was mostly low certainty.
- Effectiveness of physical, psychological, and alternative interventions for post-COVID-19 condition: a systematic review.2026 · systematic review
Summary
This systematic review asked whether supervised physical, psychological and alternative non-pharmacological treatments help adults with post-COVID-19 condition. It included 27 randomized trials with 1,998 participants; trials were supervised and face-to-face and compared interventions with usual care, placebo/sham or active comparators. Interventions included cardiopulmonary rehabilitation, multimodal and unimodal exercise, CBT and lifestyle programmes, neuromodulation, oxygen therapies, acupuncture and balneotherapy. Intervention durations varied. The review reported that cardiopulmonary rehabilitation and multimodal exercise consistently improved cardiorespiratory fitness and walking capacity; CBT and lifestyle adjustments significantly reduced fatigue and subjective concentration complaints. Examples recorded: in 114 participants, CBT lowered CIS-fatigue by a between-group mean difference of −8.8 points (95% CI −11.9 to −5.8); in 70 participants, active HD-tDCS plus rehabilitation lowered MFIS total fatigue by a between-group difference of −14.03 points (95% CI −20.28 to −7.78). Findings for neuromodulation, complementary and oxygen therapies were heterogeneous, often showing no benefit over placebo. For example, HBOT did not produce significantly greater improvements than sham on any primary or secondary outcome. Side effects and withdrawals were not reported in the recorded data. The authors state that the evidence does not support definitive conclusions about the effectiveness of any intervention category.
- Exercise effectiveness on fatigue in Long-COVID: systematic review and meta-analysis.2026 · systematic review
Summary
This systematic review and meta-analysis examined exercise for fatigue in adults with Long COVID (symptoms ≥3 months). The authors searched 7 databases in July 2025 and included 14 randomized controlled trials. Exercise groups were compared with usual care. In pooled analyses, the exercise group increased grip strength by 3.86 kg (MD 3.86 kg, 95% CI 2.23-5.50; P < .00001), respiratory muscle strength by 15.54 cmH2O (MD 15.54 cmH2O, 95% CI 8.73-22.34; P < .00001), and 6-minute walk distance by 93.57 m (MD 93.57 m, 95% CI 60.34-126.80; P < .00001). Sit-to-stand repetitions increased (SMD 1.43, 95% CI 0.40-2.46; P = .006) and sit-to-walk speed decreased by 1.23 s (SMD −1.23, 95% CI −2.11 to −0.34; P = .007). The exercise group reduced dyspnea incidence (RR 0.33, 95% CI 0.19-0.56; P < .0001), dyspnea severity (SMD −0.89, 95% CI −1.52 to −0.27; P = .005), fatigue incidence (RR 0.45, 95% CI 0.28-0.74; P = .002), and fatigue severity (SMD −0.59, 95% CI −0.96 to −0.21; P = .002). Subgroup analyses for fatigue severity found multimodal exercise reduced fatigue severity (SMD −0.45, 95% CI −0.85 to −0.06; P = .03), whereas single-modality exercise did not (SMD −0.84, 95% CI −1.71 to 0.03; P = .06). Attrition rates ranged from 0% to 30.38%; no adverse events were reported in the included studies, but most trials provided limited information regarding PEM monitoring and adverse event ascertainment. The authors describe the certainty of evidence as moderate to very low.
- Post-Covid Respiratory Rehabilitation: A Systematic Review of Physiotherapy Protocols Across Countries2026 · systematic review · preprint
Summary
This systematic review and meta-analysis asked whether physiotherapy-based respiratory rehabilitation helps people with post-COVID-19 conditions. It included 35 randomized controlled trials with 2,128 participants recruited from hospital, outpatient rehabilitation, community, or other clinical settings across countries. Interventions included pulmonary rehabilitation, aerobic and resistance exercise, breathing exercises, inspiratory muscle training, home-based rehabilitation, and telerehabilitation; duration and delivery varied. Comparators included usual or standard medical care, no intervention, wait-list control, attention control, or alternative rehabilitation approaches. Outcomes included the six-minute walk distance, FEV₁, FVC, oxygen saturation, respiratory muscle strength, dyspnoea, fatigue, and health-related quality of life. The review concluded that rehabilitation improves functional exercise capacity, with low certainty, while effects on pulmonary function remain uncertain; FEV₁ and FVC effects were not statistically significant. Evidence for dyspnoea, fatigue, quality of life, respiratory muscle strength, and oxygen saturation generally favoured rehabilitation but was heterogeneous. The review stated rehabilitation was generally well tolerated with no significant adverse events, though safety reporting was inconsistent. People who worsened or stopped treatment were not reported. The authors state that protocols varied considerably, which may have contributed to heterogeneity, and that methodological limitations reduced certainty.
- Effectiveness of inspiratory muscle training and multicomponent physical training in patients with post-COVID conditions: a systematic review and meta-analysis.2025 · systematic review
Summary
The review included seven randomized clinical trials with 449 participants with post-COVID condition persisting more than 12 weeks; studies came from Spain, Brazil, Jordan, and the UK. Participants received inspiratory muscle training (IMT) or multicomponent physical training (MPT), mostly for 8 weeks with one IMT study using 12 weeks and MPT lasting 8 to 16 weeks, compared with no intervention, WHO recommendations, or similar placebo devices. Outcomes included MIP, VO2max, handgrip strength, sit-to-stand, timed up and go, PCFS, SF-12/SF-36, FSS, FEV1/FVC, and dyspnea. IMT improved MIP (MD = 22.70), VO2max (MD = 4.49), and physical functioning (SMD = 0.32); HGS and fatigue showed no significant differences, and dyspnea findings were mixed/uncertain. MPT improved HGS (MD = 3.05), STS (MD = 3.55), TUG (MD = −1.13), PCFS (MD = −0.64), SF-12/SF-36 physical functioning (SMD = 0.72), and FSS (MD = −2.41; sensitivity MD = −1.10). No significant change was found for VO2max or FEV1/FVC with MPT. One control patient worsened; McNarry et al. reported 69% dropout; one MPT participant abandoned due to low adherence; three patients withdrew; Longobardi et al. reported nine lost. No adverse effects were reported during or after IMT or MPT. The authors rated certainty of evidence as low.
- Effectiveness of physiotherapy modalities on persisting dyspnoea in long COVID: A systematic review and meta-analysis.2025 · systematic review
Summary
This systematic review and meta-analysis asked whether physiotherapy treatments reduce persisting dyspnoea in long COVID. The reviewers searched MEDLINE, PEDro, WOS, Scopus, VHL and the Cochrane Library for studies published between September 1st, 2019 and July 2nd, 2023; the protocol was registered as CRD42023427464. They included comparative trials of adults with persistent breathlessness following COVID-19, regardless of initial severity, in whom physiotherapy was implemented as treatment for dyspnoea. 19 studies including 1292 adults fulfilled the inclusion criteria. Treatments were grouped as high-intensity rehabilitation, low-to-moderate intensity rehabilitation, respiratory muscle training, and other/passive techniques; dyspnoea was assessed with dyspnoea-specific, functional, or health-related quality-of-life scales. The authors report that physiotherapy and especially pulmonary rehabilitation may help alleviate respiratory symptoms. They state that high-intensity rehabilitation shows particularly more promising results than low-to-moderate rehabilitation or respiratory muscle training, whereas results for low-to-moderate intensity and respiratory muscle training groups were non-significant. For low-level laser therapy, the review states it seems to have significantly reduced dyspnoea and markers of inflammation in people with long-covid. The recorded data include no side-effect, worsening, or withdrawal counts. The authors state limitations including heterogeneity of interventions and controls, risk of bias from open or assessor-only blind studies, and short-term follow-up.
- Effects of therapeutic interventions on long COVID: a meta-analysis of randomized controlled trials.2025 · systematic review
Summary
This meta-analysis pooled 51 RCTs with 4026 participants with Long COVID, searching PubMed, Cochrane Library, Embase, Web of Science, SPORTDiscus (EBSCO), CINAHL (EBSCO), and Rehabilitation & Sports medicine source (EBSCO) to July 20, 2025. Trials compared exercise training, respiratory muscle training, telerehabilitation, tDCS, olfactory training, steroid sprays, or PEA-LUT with no intervention, standard primary care, or placebo; follow-up ranged from 14 to 180 days. Outcomes included cardiopulmonary function, exercise capacity, fatigue, dyspnea, and olfactory recovery. Exercise training showed significant better 6MWT (MD 83.20; 95% CI 52.04–114.37) and 30sSTS (MD 3.05; 95% CI 1.96–4.13), but no significant difference for HADS-depression, HADS-anxiety, SF-12-PCS, FVC (% predicted), FEV1, VE/VO2, VE, RER, or FEV1/FVC. Respiratory muscle training showed significant better 6MWT (MD 89.54; 95% CI 9.86–169.23) and MIP (cm H2O) (MD 19.69; 95% CI 10.14–29.24), with no significant difference for FVC, FEV1, MFIS, HADS, or MEP. Telerehabilitation showed significant better 6MWT (MD 34.14; 95% CI 2.54–65.74), 30sSTS (MD 1.41; 95% CI 0.67–2.15), and FSS (MD −1.59; 95% CI −2.64 to −0.53). tDCS showed significant lower MFIS-physical (MD −2.29; 95% CI −4.36 to −0.22). Olfactory training and steroid sprays showed no significant differences; PEA-LUT showed significant higher TDI Score (MD 4.66; 95% CI 2.16–7.15). No side-effect or withdrawal counts were reported; the authors noted exercise may pose a risk of symptom exacerbation in post-exertional malaise. They reported high risk of bias in 33 studies and high heterogeneity.
- Clinical efficacy of exercise in the treatment of post-COVID-19 syndrome: a systematic review and network meta-analysis.2025 · systematic review
Summary
This systematic review and network meta-analysis asked whether exercise therapy helps post-COVID-19 syndrome (PCS), described as persistent or new symptoms beyond the acute phase of SARS-CoV-2 infection. The authors searched PubMed, Embase, Web of Science, and Ovid through 25 March 2025 and included 33 randomized controlled trials with 2,895 participants. Exercise interventions were grouped as aerobic exercise (AE), respiratory muscle training (RMT), resistance training (RT), combinations, or no exercise therapy. Outcomes included FEV1/FVC, peak VO2, six-minute walk test (6MWT), mMRC dyspnea score, and Mental Health/Mental Component Summary scores. For FEV1/FVC, AE + RMT ranked highest (97.62%), followed by AE (76.33%) and RMT (40.62%); the text states AE + RMT was better than the other treatments except AE, while AE was better than no exercise therapy. For peak VO2, the experimental group had a statistically significant reduction compared with control (Z = 3.02, P = 0.003; I2 = 0%). The 6MWT distance showed a statistically significant advantage for the experimental group (Z = 6.13, P < 0.00001; I2 = 83%), and AE + RMT + RT was better than no exercise intervention (Z = 14.26, P < 0.00001; I2 = 0%). mMRC was better in the experimental group (Z = 2.88, P = 0.004; I2 = 95%). MH (Z = 2.63, P = 0.008; I2 = 0%) and MCS (Z = 4.09, P < 0.0001; I2 = 10%) were significantly better in the experimental group than in the control group. No difference, worsening, stopping, or side-effect counts were reported in the text provided.
- Effects of Physical Exercise on Functional Physical Performance in Individuals With Long COVID: A Systematic Review.2025 · systematic review
Summary
This systematic review asked whether physical exercise changes functional physical performance in people with long coronavirus disease-2019 (COVID-19). Seven studies were reviewed; interventions lasted 2 to 16 weeks, with frequencies of 2 to 7 days per week. Search databases included MEDLINE, EMBASE, Web of Science, Scielo, SPORTDiscus and CINAHL. The included studies compared exercise programmes with control conditions such as standard physiotherapy, usual care, home rest, medical care and advice, or home-based guidelines. Outcomes covered strength, cardiorespiratory fitness, agility/mobility, anxiety, depression, quality of life, dyspnea and fatigue. Strength improved in 67% of studies, cardiorespiratory fitness in 50%, and agility/mobility in 60%. Anxiety improved in 25% of studies, depression in 75%, and quality of life across all studies (5 out of 5). Dyspnea improved in 40% and fatigue in 80% of studies. Adverse effects were assessed in five studies, which did not report their occurrence. Worsening and stopping were not reported. The authors conclude that results suggest potential benefits of exercise training in several outcomes, mainly functional capacity, depression symptoms, quality of life and fatigue. They state limitations: the studies evaluated show a varied population, including hospitalized and non-hospitalized individuals; the absence of a standardized therapeutic protocol with interventions of varying duration makes it difficult to understand the effects; and the small sample size restricts generalization and the ability to detect significance.
- The effects of inspiratory muscle training on exercise tolerance in patients with post-covid-19 syndrome: a systematic review.2025 · systematic review
Summary
This systematic review asked whether inspiratory muscle training (IMT), alone or combined with aerobic and resistance exercises, affects exercise tolerance and respiratory function in adults with post-COVID-19 syndrome. The reviewers included six randomized controlled trials encompassing a total of 451 participants, all published in peer-reviewed journals. The review compared IMT with control groups. Reported outcomes included inspiratory muscle strength, diaphragmatic thickness, distance covered in the 6-min walk test (6MWT), maximal oxygen uptake (VO2 max), and autonomic modulation. Compared with control groups, IMT demonstrated significant improvements in inspiratory muscle strength, diaphragmatic thickness, and distance covered in the 6MWT. However, no consistent differences were observed in maximal oxygen uptake (VO2 max) or autonomic modulation, and there was no significant difference between IMT and control in autonomic modulation. The authors describe the overall quality of evidence as moderate, noting small sample sizes and heterogeneous protocols, and state that the available evidence remains limited and heterogeneous. They conclude that combined IMT improves exercise tolerance in post-COVID-19 patients but call for multicenter RCTs with standardized protocols and long-term follow-up. Duration of IMT and follow-up were not reported in the provided text. Side effects and withdrawals were not reported in the provided text.
- Post-Acute COVID-19 Syndrome (PACS) and Exercise Interventions: A Systematic Review of Randomized Controlled Trials.2025 · systematic review
Summary
This systematic review asked whether exercise interventions affect health-related quality of life and functional fitness in adults with Post-Acute COVID-19 Syndrome. It searched databases and clinical registers up to July 2025 and included 20 randomized controlled trials. Exercise programmes varied: aerobic training, resistance or concurrent training, breathing exercises, strength-based exercises, pilates, yoga disciplines and telerehabilitation; one study used continuous aerobic training at 50% of workload. Durations included a 2-week protocol and an 8-week protocol. Comparators included usual care, waitlist, no intervention, general guidance, another exercise setting or another exercise delivery. Outcomes were HRQoL and functional fitness. Some trials reported significant HRQoL improvements (Refs. [30,39,46]) and positive SF-12 physical and mental components (Refs. [27,29,35]). Ref. [32] found no significant quality-of-life change between supervision by a general or specialized physiotherapist, though the SF-12 physical component changed. Ref. [33] found virtual reality was not superior to traditional methods. Ref. [31]’s 2-week breathing- and strength-based protocol and Ref. [41]’s 8-week breathing, pilates and yoga protocol were described for respiratory function. Overall dropout rates were below 37%; treatment-attributed harms were not reported. The authors state limits include heterogeneity of protocols and non-comparable frequency, duration, and modality.
- Effect of pulmonary rehabilitation for patients with long COVID-19: a systematic review and meta-analysis of randomized controlled trials.2025 · systematic review
Summary
This systematic review and meta-analysis asked whether pulmonary rehabilitation affects adults with long COVID-19. The authors searched randomized controlled trials published before April 2024 and included 37 studies with 3363 patients. Pulmonary rehabilitation was compared with controls receiving usual care, no treatment, educational material, a sham device, or unsupervised rehabilitation. Programs were grouped by duration (≤4, 4–8, and >8 weeks) and by exercise type (breathing, multicomponent, or both). Outcomes included 6MWT, lung function (FEV1, FVC, MIP, MEP), HRQoL, fatigue, 30STST, handgrip, dyspnea, depression, anxiety, perceived effort, and adverse events. The review reports improvement in 6MWT with a mean difference of 77.95 m (95% CI 50.91–104.99 m), and improvements in 30STST, handgrip, lung function, HRQoL, fatigue, dyspnea, and anxiety, but no effect on depression was detected. Subgroups: ≤4 weeks improved 6MWT but not FEV1, FVC, HRQoL, or fatigue; 4–8 weeks improved 6MWT, FEV1, FVC, HRQoL, and fatigue; >8 weeks improved HRQoL and fatigue but no additional 6MWT, FEV1, or FVC. Breathing exercises improved 6MWT, lung function, and HRQoL without fatigue effect; multicomponent exercises improved 6MWT and fatigue without lung function or HRQoL effects; combined exercises improved 6MWT, FEV1, FVC, HRQoL, and fatigue. Adverse events were reported in 16 RCTs: nine found none in either group; two reported events in both groups; one reported minor oxygen desaturations in the intervention group; three reported control-group events; one reported reinfection without specifying group. GRADE certainty was low to moderate, and the authors state bias may have overestimated outcomes.
- The effect of pulmonary rehabilitation for post-acute sequelae of SARS-CoV-2 infection in patients: a systematic review and meta-analysis.2025 · systematic review
Summary
This systematic review and meta-analysis examined pulmonary rehabilitation for adults with post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. Ten randomized controlled trials involving 673 participants were included; trials were identified through a search of PubMed, Embase, Web of Science, and the Cochrane Library. Pulmonary rehabilitation was compared with usual care, no treatment, educational materials, or a sham device, and duration varied across trials. Outcomes included six-minute walk distance, dyspnea, fatigue, quality of life, and maximal inspiratory pressure. Compared with usual care, pulmonary rehabilitation improved six-minute walk distance (mean difference 76.85 meters; 95% CI 57.35–96.36; p < 0.001), maximal inspiratory pressure (mean difference 17.63 cmH2O; 95% CI 4.50–30.76; p = 0.009), fatigue (SMD −1.15; 95% CI −1.83 to −0.48; p < 0.001), and quality of life (SMD 1.73; 95% CI 0.55–2.91; p = 0.004). The pooled dyspnea result favored pulmonary rehabilitation but was not statistically significant (mean difference −0.41; 95% CI −1.51 to 0.68; p = 0.46). Subgroup analyses found no statistically significant differences between telerehabilitation and face-to-face pulmonary rehabilitation for exercise capacity (p = 0.84), dyspnea (p = 0.86), fatigue (p = 0.93), or quality of life (p = 0.44). The review did not report counts of participants who stopped or side effects; it noted that patients with post-exertional symptom exacerbation may not benefit from traditional aerobic-based pulmonary rehabilitation and may even deteriorate. The authors state limitations include substantial heterogeneity, limited eligible RCTs and small sample sizes, possible missed studies, and lack of long-term follow-up.
- Physical Training Protocols for Improving Dyspnea and Fatigue in Long COVID: A Systematic Review with Meta-Analysis.2025 · systematic review
Summary
This systematic review with meta-analysis asked which physical training protocols are used by people with long COVID to alleviate dyspnea and fatigue. The search was conducted in October 2023; 25 articles were included. The review included primary experimental studies of individuals living with long COVID; its comparison was “not applicable.” Training protocols were mostly combinations of methods, most commonly respiratory muscle training with strength and aerobic training. Other protocols included concurrent training, inspiratory muscle training (IMT), concurrent training with IMT, a self-directed program following WHO recommendations, and aerobic training alone. The text does not report a single duration for these protocols. Dyspnea and fatigue were assessed with questionnaires. Of the 17 studies that assessed dyspnea, 11 showed significant improvement after physical exercise rehabilitation; of the 20 that assessed fatigue, 10 showed significant improvement after physical training. A meta-analysis of two studies found no significant effect on reducing fatigue compared with the control group (intervention participants: 37; control: 38; 95% CI: 15.42 to 8.77; I2: 89%). A study showed periods of worsening fatigue and dyspnea as a fluctuating pattern, and in some sessions an increase in fatigue and dyspnea intensity after excessive effort. Stopping and side effects were not reported. The authors state most studies had a moderate to high risk of bias and heterogeneity limited a more comprehensive meta-analysis.
- Effectiveness of pulmonary rehabilitation programmes and/or respiratory muscle training in patients with post-COVID conditions: a systematic review.2024 · systematic review
Summary
This systematic review asked whether pulmonary rehabilitation programmes and/or respiratory muscle training affect respiratory sequelae in people with post-COVID-19 condition. The authors searched PubMed, PEDro, Embase, Cochrane, Scopus, and Web of Science and included five randomized trials with 52, 32, 60, 39, and 80 participants. The trials compared different supervised, non-virtual programmes: diaphragm release plus inspiratory muscle training versus inspiratory muscle training; virtual-reality pulmonary rehabilitation versus traditional pulmonary rehabilitation; aerobic, muscle-strengthening, and respiratory exercise versus the same plus an active cycle of breathing technique; a tailored multicomponent exercise programme versus WHO guidelines; and multicomponent exercise, inspiratory muscle training, both combined, or WHO guidelines. Outcomes included 6-minute walk test distance, dyspnea, fatigue, lung function, maximum inspiratory pressure, and quality of life. Findings varied by trial. For maximum inspiratory pressure, one trial reported an increase of 48.17% (p < 0.001) in the intervention group with no significant change in the control group. For 6-minute walk test distance, one trial reported greater improvement in the intervention group (p < 0.001); another reported improvement in both groups with no significant between-group difference; another reported improvement in both groups (p > 0.001), with Group B improving 21.61% and Group A 11.09%. Dyspnea and fatigue results were mixed across trials. Quality of life improved in one trial (p = 0.003) and showed no significant change in any of four groups in another. Side-effect counts for the included trials were not reported. The authors state that a limited number of trials met the criteria.
- The pulmonary rehabilitation effect on long covid-19 syndrome: A systematic review and meta-analysis.2024 · systematic review
Summary
This systematic review and meta-analysis asked whether pulmonary rehabilitation improves dyspnea, fatigue, physical function, quality of life, anxiety and depression in adults with long COVID-19, and compared face-to-face with telerehabilitation. It included 16 studies and 1027 adults; searches covered PubMed, Web of Science, and Cochrane Library to January 2023. Pulmonary rehabilitation was delivered face-to-face or by telerehabilitation, and comparisons included usual care, sham procedures, or no control. Outcomes were dyspnea, physical function, quality of life, anxiety, depression and fatigue. Meta-analysis found significant effects on dyspnea (SMD = 1.29, 95% CI [0.43 to 2.15]; I2 = 93.7%), physical function (SMD = −0.60, 95% CI [−0.96 to −0.25]; I2 = 85.4%), global quality of life (SMD = −1.07, 95% CI [−1.70 to −0.45]; I2 = 94.7%), mental quality of life (SMD = −0.36, 95% CI [−0.53 to −0.19]; I2 = 0%), physical quality of life (SMD = −0.68, 95% CI [−0.95 to −0.41]; I2 = 61.1%), anxiety (SMD = 0.32, 95% CI [0.16 to 0.48]; I2 = 4%) and depression (SMD = 0.37, 95% CI [0.18 to 0.56]; I2 = 16.4%). Fatigue was not significant (SMD = 0.61, 95% CI [−0.10 to 1.32]; I2 = 91%). Face-to-face physical quality of life improved (SMD = −0.91, 95% CI [−1.13 to −0.69]), while telerehabilitation did not (SMD = −0.23, 95% CI [−0.47 to 0.02]). No harms or withdrawals were recorded in the extracted data. The authors state limits including small sample sizes and high risk of bias.
- Interventions for the management of long covid (post-covid condition): living systematic review.2024 · systematic review
Summary
This living systematic review assessed drug and non-drug interventions for long covid in adults. It included 24 unique trials with 3695 patients, predominantly from the Americas or Europe. One trial (n=114) compared an online CBT programme called “fit after covid” with usual care; moderate certainty evidence suggested CBT probably reduces fatigue (mean difference −8.4, 95% CI −13.11 to −3.69) and probably improves concentration (mean difference −5.2, −7.97 to −2.43). One trial (n=585) compared combined physical and mental health rehabilitation with one session of online advice and support; moderate certainty evidence suggested it probably increases recovery or important improvement (161 more per 1000 patients, 95% CI 61 more to 292 more), improves quality of life (mean difference 0.04, 95% CI 0.00 to 0.08), and reduces depression (mean difference −1.50, −2.41 to −0.59), with little or no effect on physical and cognitive function or anxiety. Intermittent aerobic exercise 3-5 times weekly for 4-6 weeks probably improves physical function compared with continuous exercise (mean difference 3.8, 95% CI 1.12 to 6.48; n=110). Vortioxetine for eight weeks did not improve cognitive function; coenzyme Q10 500 mg/day for six weeks probably did not improve quality of life (n=119); SIM01 might alleviate fatigue (200 more per 1000 patients, 95% CI 94 more to 336 more; n=463) but probably did not improve quality of life. No instances of post-exertional malaise were reported in the rehabilitation trial; effects on serious adverse events were very uncertain.
- Effectiveness of Rehabilitation Interventions on Adults With COVID-19 and Post-COVID-19 Condition. A Systematic Review With Meta-analysis.2024 · systematic review
Summary
This systematic review with meta-analysis asked whether rehabilitation interventions help adults with COVID-19 or post COVID-19 condition (PCC). It included 40 studies with 2445 participants; patients were adults hospitalized in any setting or discharged at home, with any COVID-19 severity or PCC. Interventions included pulmonary rehabilitation, self-activities, qigong exercise and acupressure rehabilitation program (QARP), yoga and naturopathy, Mandala coloring, cognitive motor training, and FES-cycling. Comparisons were usual care or no intervention. Pooled analyses compared pulmonary rehabilitation with usual care in post COVID-19 patients: exercise capacity favored pulmonary rehabilitation (MD 65.06, 95% CI 42.87 to 87.25; 2 studies, 184 participants); FEV1 favored pulmonary rehabilitation (MD 0.16, 95% CI 0.05 to 0.28; 2 studies, 179 participants); FEV1/FVC favored pulmonary rehabilitation (MD 0.05, 95% CI 0.01 to 0.09; 2 studies, 174 participants); FVC showed no effect (MD 0.19, 95% CI -0.03 to 0.42; 2 studies, 179 participants). Self-activities plus usual care compared with usual care showed an anxiety effect (MD -12.03, 95% CI -21.16 to -2.90; 2 studies, 207 participants). Narrative findings said QARP and “twist and raise” walking technique seem to reduce dyspnea and weakness; yoga and naturopathy, Mandala coloring, and respiratory exercise seem to reduce anxiety and depression; cognitive motor training seems to improve cognitive function; FES-cycling seems useful for erect position restoration and walking capacity. Li 2022 reported no serious adverse events; another study reported headache and dizziness events but no significant difference between groups. Worsening or stopping was not reported. The authors state very uncertain evidence and very low certainty.
- The effectiveness of exercise in alleviating long COVID symptoms: A systematic review and meta-analysis.2024 · systematic review
Summary
This systematic review and meta-analysis examined exercise interventions for long COVID symptoms. Nine studies involving 672 individuals were included; trials were based in eight countries, mainly in Europe and the Western Middle East. The included RCTs compared exercise with active or passive controls such as usual care, waitlist, exercise education, and sham respiratory devices. Exercise types included supervised combined aerobic and resistance exercise, aerobic exercise, multimodal exercise, breathing exercise, inspiratory muscle training, and Taichi, with printed durations such as 2-week, 5-week, 6-week, 8-week, 10-week, and 12-week. Outcomes were fatigue, dyspnea, anxiety, depression, and cognitive impairment. Exercise significantly improved long COVID fatigue (ES = 0.89, 95% CI: 0.27 to 1.50) and dyspnea (ES = 1.21, 95% CI [0.33, 2.09]), whereas no significant effect was identified on long COVID anxiety, depression, and cognitive impairment. Reported harms included symptom exacerbation in the sham group (One person/88) and dizziness (One minor/150); withdrawals included 57/148 and 21 dropouts. The authors state most included studies used subjective measurements and were at high risk of bias, and long-term effects remain unknown.
- Respiratory Muscle Strength Training in Patients Post-COVID-19: A Systematic Review.2024 · systematic review
Summary
This systematic review evaluated respiratory muscle strength training for individuals with post-COVID-19 dyspnea. The authors searched CINAHL, Web of Science, PubMed, EMBASE, Google Scholar, and Scopus for articles from 2020-2023; eleven articles met the inclusion criteria. The abstract does not report how many participants were included, the treatment duration, the comparison conditions, or the settings of the included studies. It states that pulmonary measures improved and that dyspnea, physical capacity and quality of life measures achieved statistical significance. The authors concluded: “Outcomes improved following respiratory muscle strength training as a standalone intervention, or with aerobic and peripheral muscle strength training.” Because this is a systematic review, that statement is the authors' conclusion across the included articles, not a finding of a new study. The abstract does not report side effects, withdrawals, or limitations. No individual study results, participant numbers, or harms are given in the abstract. The abstract also gives no details about the included study designs or participant characteristics.
- Rehabilitation Interventions for Physical Capacity and Quality of Life in Adults With Post-COVID-19 Condition: A Systematic Review and Meta-Analysis.2023 · systematic review
Summary
This systematic review with bayesian meta-analysis searched MEDLINE, Scopus, CINAHL, and the Clinical Trials Registry from January 2020 until February 2023 and included 14 trials (1244 patients; 45% female participants; median [IQR] age, 50 [47 to 56] years) with post–COVID-19 condition. It examined respiratory training and exercise-based rehabilitation interventions against placebo, usual care, waiting list, or control. The median follow-up for the primary outcome was 6 (5.5-7.0) weeks. For functional exercise capacity (6-minute walking test; 7 trials, 389 participants), the pooled SMD was −0.56 (95% CrI, −0.87 to −0.22). For lower limb muscle function (4 trials, 371 participants), the SMD was −0.77 (95% CrI, −1.94 to 0.44), with uncertain magnitude and direction. Dyspnea (8 trials, 573 participants) had SMD −1.00 (95% CrI, −1.94 to −0.10). FEV1 (6 trials, 363 participants) showed no difference: SMD −0.16 (95% CrI, −0.42 to 0.11); FVC showed no difference: SMD −0.13 (95% CrI, −0.38 to 0.12). Overall quality of life (5 trials, 366 participants) had SMD −0.41 (95% CrI, −0.73 to −0.06). Adverse events: OR 1.68 (95% CrI, 0.32 to 9.94); Five trials gave no adverse-event information, four trials (5 records) reported no related adverse events, and adverse events were reported in 5 trials. Fatigue evidence was limited and could not be synthesized. Worsening or stopping was not reported.
- Long COVID and Physical Therapy: A Systematic Review.2023 · systematic review
Summary
The review searched Scopus, PubMed, Cinahl and WOS and included six studies of adults with long COVID or a post-COVID-19 condition. It aimed to analyse treatment programmes for long COVID based on physical activity. Interventions included inspiratory muscle training, pulmonary tele-rehabilitation, multicomponent exercise, resistance and aerobic training, and an online breathing and well-being programme. Durations reported were 12 weeks for a home inspiratory muscle training programme, 6 weeks for pulmonary tele-rehabilitation, 8 weeks in two exercise studies, 6 weeks for the online programme, and eight weeks for inspiratory muscle training. Study sizes were 26, 30, 80, 39, 192 and 281 participants. The review states that all studies except McNarry’s had statistically significant results, with the intervention group showing statistically significant results compared with control groups. Drop-outs were reported for personal reasons, difficulty attending and deterioration; no counts were given. The authors conclude that these investigations support the hypothesis that physical activity interventions may have positive effects on post-COVID recovery. They state limitations from sample sizes, potential for bias, inadequate control of confounding variables and even the cross-sectional approach.
- Efficacy and Safety of Respiratory Telerehabilitation in Patients with Long COVID-19: A Systematic Review and Meta-Analysis.2023 · systematic review
Summary
This systematic review and meta-analysis asked whether respiratory telerehabilitation helps adults with Long COVID-19. The authors searched MEDLINE, Scopus and PEDro from database inception until July 2023 and included 10 randomized controlled trials, with 866 patients with Long COVID-19. Trials compared respiratory telerehabilitation with no intervention, usual care, placebo, or face-to-face intervention. The review pooled quality of life, dyspnea, lung function, anxiety and depression, respiratory muscle strength, functional capacity, lower limb strength and adverse events. The meta-analysis reported significant differences in favour of respiratory telerehabilitation for quality of life (SMD = 0.59; 95% CI = 0.09; 1.09; p = 0.02), dyspnea (SMD = 4.95; 95% CI = 2.81; 7.08; p < 0.00001), respiratory muscle strength (MD = 13.71; 95% CI = 5.41; 22; p < 0.001), functional capacity (SMD = 0.75; 95% CI = 0.39; 1.11; p < 0.0001), and lower limb strength (SMD = 0.67; 95% CI = 0.15; 1.18; p = 0.01). It reported non-significant differences for FVC (MD = 0.21; 95% CI = −0.17; 0.60; p = 0.28) and anxiety and depression (SDM = −0.05; 95% CI = −0.23; 0.12; p = 0.55). For adverse events, the difference between groups was not statistically significant (OR = 0.53; 95% CI = 0.27; 1.02; p = 0.06).
- Complementary and alternative medicine for long COVID: a systematic review of randomized controlled trials.2023 · systematic review
Summary
This systematic review examined complementary and alternative medicine (CAM) for long COVID. The authors searched multiple databases and clinical trial registries and included 14 randomized controlled trials with 1195 participants. Trials tested self-administered transcutaneous auricular vagus nerve stimulation, olfactory training, dietary supplements, neuro-meditation, aromatherapy, inspiratory muscle training (IMT), concurrent training, and an online breathing and well-being program. The review reported that taVNS was associated with a mild-to-moderate effect in reducing mental fatigue symptoms; olfactory training improved subjective but not objective olfactory function and reduced parosmia; CoQ10 showed no significant difference from placebo for overall health status or post-COVID-19 symptoms; neuro-meditation improved fatigue, pain, mood, sleep, and cognitive functioning; aromatherapy improved post-COVID-19 fatigue; IMT improved breathlessness recovery, exercise capacity, and quality of life; concurrent training was associated with better outcomes than self-care recommendations and IMT alone; and L-arginine plus vitamin C improved walking performance, muscle strength, endothelial function, and fatigue. Reported harms included mild skin irritation, headache, dizziness, nausea, constipation, diarrhea, abdominal pain, heartburn, and muscle pain. One participant withdrew with headaches, one with dizziness, and seven with excessive fatigue. No serious adverse events were noted.
- Rehabilitation and COVID-19: systematic review by Cochrane Rehabilitation.2023 · systematic review
Summary
This systematic review asked what evidence exists on interventions for rehabilitation for COVID-19-related limitations of functioning in adults with COVID-19 or post COVID-19 condition (PCC). It included 53 RCTs with 3882 randomized participants; included adults were hospitalized or managed at home, and the review covered non-severe, severe, critical COVID-19 and PCC. Interventions were compared with usual care, sham/placebo, no treatment, or another active intervention; duration was not reported. Outcomes covered body functions, activities and participation, quality of life, and adverse events. The review synthesized evidence narratively. It reports that the effect of breathing and strengthening exercise programs on dyspnea and physical exercise capacity compared to no treatment in non-severe COVID-19 patients is uncertain. Multicomponent telerehabilitation may slightly increase physical exercise capacity compared to educational intervention in adults with PCC, but uncertainty remains about its effect on lung function and physical exercise capacity compared to no treatment; it reported no evidence of an effect on FVC and FEV1/FVC% for multicomponent telerehabilitation compared to no treatment in PCC. The effect of inspiratory muscle training on maximal inspiratory pressure compared to no treatment in adults with PCC is uncertain. For harms, four grouped studies and fourteen studies reported no adverse events; five and three mild adverse events (transient skin redness) occurred in active HD-tDCS and sham groups, respectively; one person in the sham group presented symptom exacerbation; olfactory training had two (0.8%) headache reports and one (0.4%) worsening parosmia report. The authors state they cannot provide robust suggestions for practice.
- Transcranial stimulation as a possible therapeutic proposal in long COVID.2026 · review
Summary
This critical review examined evidence on neuromodulation for long COVID; it reports no new study participants. It summarized named trials and cases. Santana et al. (2023) enrolled 70 patients with post-COVID fatigue and reported significantly reduced fatigue on the MFIS with HD-tDCS versus sham. Andrade et al. (2022) studied 56 adults after mechanical ventilation and reported significantly increased ventilator-free days in the first 28 days versus controls. Oliver-Mas et al. (2023) studied 47 post-COVID patients with persistent fatigue; active tDCS significantly reduced physical fatigue immediately and at 1-month follow-up and reduced depressive symptoms, while cognitive fatigue and quality of life did not show significant improvements. In Oliver-Mas et al. (2025), M1 stimulation showed slight superiority for fatigue and sleep. Vidal et al. (2025) reported modest but significant improvements in inhibitory control, processing speed, and divided attention. Klírová et al. (2024) found no significant improvement in cognitive function. Souza et al. (2024) reported respiratory improvements in six patients; Gómez et al. (2021) reported reduced HARS, HDRS, and MFIS scores in a 58-year-old patient. A cited meta-analysis of 51 randomized trials with 4,026 participants reported improved functional capacity and reduced dyspnea and fatigue, but no consistent effects on spirometric parameters, global fatigue, or anxiety and depression. Adverse effects in Oliver-Mas et al. (2023) were mild; the review states adverse events were limited to mild and transient skin discomfort.
- Assessment and management of post-COVID-19 pulmonary complications: a rapid review.2026 · review
Summary
This rapid review assessed evidence on management and treatment of pulmonary complications in post-COVID-19 condition (PCC). It included 73 unique records from published and grey literature; these comprised guidance documents, secondary studies and primary research studies. Included primary studies involved adults with PCC and pulmonary complications, with individual study sizes that included 28 and 871 participants. Interventions included IHHT plus standard rehabilitation, nirmatrelvir plus ritonavir, hyperbaric oxygen, systemic corticosteroids, and multicomponent exercise rehabilitation. Comparisons included standard rehabilitation, placebo plus ritonavir, sham treatment, nonsteroid care, and usual care or control. Outcomes included 6MWT distance, Borg and PROMIS dyspnoea, RAND-36 physical function, FEV1, FVC, FVC % pred, resting oxygen requirement and adverse events. Doehner 2024 reported a significant between-group difference in 6MWT distance favouring IHHT plus rehabilitation (p<0.001). Geng 2024 found no between-group difference in PROMIS dyspnoea (p>0.05). Kjellberg 2025 found no difference in RAND-36 physical function (p=0.277) or 6MWT distance (p=0.62) with hyperbaric oxygen versus sham. Ntiamoah 2024 reported significant improvements in FEV1, FVC and FVC % pred in the steroid group only. Torres 2024 reported FVC % pred improved from 52±0.17% to 60±0.20% (p=0.019) and resting oxygen requirement reduced (p=0.005), with no significant change in 6MWT distance (p=0.50). Seo 2025 reported diarrhoea in 80% of patients with nintedanib; Ora 2023 reported no adverse events with sodium pyruvate nasal spray. The authors state study quality and risk of bias were heterogeneous and findings should be interpreted with caution.
- Physiotherapy management of long COVID in adults.2026 · review
Summary
This invited topical review does not report its own study; it summarises physiotherapy management of long COVID in adults, enrols no patients, and reports no treatment duration for its own data. It describes exercise-based rehabilitation, respiratory muscle training, breathing retraining, management of postural orthostatic tachycardia syndrome, cognitive impairment, self-management and models of care. It reports findings from cited studies. For exercise-based rehabilitation, a recent systematic review is described with 12 trials for 6-minute walk distance (SMD 1.14; I2 = 79%), 5 trials for dyspnoea (SMD 1.40; I2 = 87%), 4 trials for fatigue (SMD 0.54; I2 = 57%), 6 trials for FVC%pred (SMD 0.08; I2 = 15%) and 5 trials for sit-to-stand (SMD 1.27; I2 = 32%). For respiratory muscle training, modified data from Tan et al. are described, and the review describes RMT as compared with usual care: 3 trials for 6-minute walk distance (SMD 1.38; I2 = 94%), 4 trials for dyspnoea (SMD 1.24; I2 = 97%), 1 trial for fatigue (SMD 0.03), 2 trials for FVC%pred (SMD 0.03; I2 = 0%) and 4 trials for maximal inspiratory pressure (SMD 0.47; I2 = 50%). A cited systematic review with seven studies reported that therapeutic exercise generally improves heart rate regulation, cardiac function and quality of life in individuals with POTS. Harms are reported from cited sources: five of the eight included studies reported on adverse events, with four of these studies reporting no adverse events during training; one study reported mild adverse events including chest tightness, feelings of weakness or reduced physical strength and cough; one participant discontinued exercise training due to chest pain; and one large trial reported that 50% of participants in the RMT group had withdrawn by the end of the trial. The authors state that high statistical heterogeneity and publication bias limit interpretation.
- Treatments for Long COVID autonomic dysfunction: a scoping review.2025 · review
Summary
This scoping review included 11 effectiveness studies, 11 guidelines/position statements, and 15 unpublished/ongoing studies of Long COVID autonomic dysfunction. Among comparative data, an NRCS in Italy gave fexofenadine 180 mg/day plus famotidine 40 mg/day to 14 patients and compared them with 13 who received no antihistamines; follow-up increased heart rate was 29% vs. 85% (p = 0.0063) and abdominal disorders 14% vs. 62%. An RCT of 463 patients compared SIM01 with placebo: fatigue alleviation 63% vs. 43% (OR 2.273, 95% CI 1.520–3.397), GI upset 70% vs. 54% (OR 1.995, 95% CI 1.304 to 3.051); quality of life 76.0 vs. 74.5 (p = 0.17) and physical activity p = 0.37 did not differ significantly. Any AE was 9.5% vs. 10.8%. Single-arm studies reported pre-post changes: maraviroc plus pravastatin (18), SSRIs (95; serious side effects 31.6% [30/95], mild 54.7% [52/95]), a nutraceutical (51), multicomponent treatment with salt/water/compression plus bisoprolol (32), HRV biofeedback (13), inspiratory muscle training (26), and SGB (41; vagal response 7.3% [3/41], transient hoarseness 9.8% [4/41]). Review authors state existing studies are often small and uncontrolled.
- Interventions for Long COVID: A Narrative Review.2025 · review
Summary
This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).
- Pharmacologic and Nonpharmacologic Treatment of Long COVID: A Meta-narrative Review2025 · review
Summary
This meta-narrative review evaluated pharmacologic and nonpharmacologic treatments for long COVID, defined as persistent symptoms 4 weeks or longer after acute COVID-19. The authors searched English-language articles from November 2019 through December 2023 and included 51 studies. Most included studies reported nonpharmacologic treatments, with fatigue the most prevalent symptom. Interventions described included therapeutic exercise, nutritional supplements, oxygen-ozone autohemotherapy, rehabilitation, molecular hydrogen therapy, hyperbaric oxygen, epipharyngeal abrasive therapy, Qingjin Yiqi granules, pomegranate juice with sumac, remdesivir, antibody-based therapies, and intranasal corticosteroids. Findings varied by study: some reported improvements in fatigue, dyspnea, cognitive symptoms, chest pain, immunodeficiency, or olfactory dysfunction. The review also reported no significant reduction in number or severity of long COVID–related symptoms with high-dose CoQ-10 compared with placebo; no significant difference in symptoms and mortality risks between nirmatrelvir/ritonavir and no treatment groups; smell score differences not statistically significant with corticosteroid nasal irrigation; and no effect of olfactory training on olfactory test scores. In Pehlivan et al., 6 cases were dropped for several reasons. The authors state the evidence is limited and of low quality.
- Health care for patients with long COVID: a scoping review.2024 · review
Summary
This scoping review examined health care for patients with Long Covid-19. It included 13 studies identified in electronic databases, carried out in several countries and published in English. Included studies reported telerehabilitation with physical exercises, physical exercise interventions, outpatient pulmonary rehabilitation, standard physical therapy, cognitive behavioral therapy with antidepressants and non-benzodiazepine tranquilizers, and supervised concurrent training with or without inspiratory muscle training; an exercise intervention was reported at 8 weeks. Some studies compared supervised therapeutic exercise with a WHO self-management rehabilitation leaflet, physical training rehabilitation with standard physical therapy, and physical exercise with breathing training and controls. Outcomes included physical capacity, quality of life, symptoms, fatigue, dyspnea, and stress, anxiety and depression. The review reports improvements after telerehabilitation in physical capacity, quality of life, fatigue and dyspnea; improvement in fatigue after physical intervention; reduction in dyspnea after 8 weeks of physical exercise; increase in 6-minute walk distance and decrease in dyspnea after outpatient pulmonary rehabilitation; maximum inspiratory mouth pressure increased by 28%; MDP score after physical training rehabilitation was 42% lower than after standard physical therapy; and improvement in stress, anxiety and depression with CBT plus antidepressants and tranquilizers. It also reports that some fatigue and quality of life results did not show significant improvements compared to the control group, and that participants reported relapses when performing physical exercise. No side-effect counts were reported. The authors state the selected studies did not provide specific guidelines and that there is a clear gap in the literature on how to identify and clinically manage people with this condition.
- Treatable traits for long COVID.2023 · review
Summary
This comprehensive review asked how a treatable traits approach could be applied to long COVID. It combined an umbrella review of 22 systematic reviews identifying long COVID symptoms and complications with a systematic review of 18 randomized controlled trials of prevention or management. The trials tested many interventions, including metformin for 14 days during acute COVID-19 versus placebo, hyperbaric oxygen therapy versus sham, exercise training or respiratory muscle training versus usual care or sham, HD-tDCS versus sham, L-arginine plus liposomal vitamin C versus placebo, aromatherapy versus inert oils, and platelet-rich plasma injections versus saline. Outcomes included long COVID incidence, cognition, olfaction, dyspnoea, fatigue, exercise capacity and health-related quality of life. In one prevention trial, metformin was associated with reduced long COVID incidence at 10 months (hazard ratio 0.58 [95% CI 0.38, 0.88]) among 564 metformin and 561 placebo participants; ivermectin and fluvoxamine showed no significant benefit. For management, hyperbaric oxygen improved cognition compared with sham (104.1 ± 7.2 versus 101.3 ± 8.9, p = 0.038), and exercise training improved exercise capacity compared with exercise advice (38.9 ± 10.8 versus 36.1 ± 9.5 mL/kg/min, p = 0.035). Some studies found no significant between-group differences, including a larger exercise trial. Adverse events included 13 during hyperbaric oxygen versus 14 during control; one aromatherapy participant withdrew on day 13 with headaches, and one sham IMT participant withdrew for symptom exacerbation. The authors state the review was limited by not conducting a meta-analysis and by heterogeneity of the included systematic reviews.
- Exercise Training in Non-Hospitalized Patients with Post-COVID-19 Syndrome-A Narrative Review.2023 · review
Summary
This narrative review summarized seven studies of exercise interventions in adults with post-COVID-19 syndrome (PCS), identified through MEDLINE and Scopus. Interventions included exercise training, pulmonary rehabilitation, digital physiotherapy, and blended community-based rehabilitation; reported program lengths included 6 weeks and 4 weeks. Some trials compared exercise with self-management rehabilitation recommendations or inspiratory muscle training. Outcomes included VO2max/VO2peak, maximal workload, 6MWT, SPPB, DASI, SF-12, EQ-5D-5L, and PCFS. Estimated VO2max increased by 2.1 mL/kg/min in EX and by 2.9 mL/kg/min in CT and 2.5 mL/kg/min in CTRM, with no changes in the control groups. VO2peak improved by 2.4 mL/kg/min; maximal workload by 21.8 W after 6 weeks of pulmonary rehabilitation; 6MWT by 68.9 m and 57.6 m; SPPB by +1.22 points after 4 weeks of digital physiotherapy. DASI and EQ-5D-5L increased. SF-12 physical domain showed a group effect from 35.7 to 47.8, while CT, CTRM, and RM showed pre–post increases without between-group differences; mental health increased in CTRM only from 39.5 to 44.8. PCFS < 2 changed from 3 to 14 with CT. No adverse events were reported. Dropouts were n = 6, n = 4, n = 1, and n = 3 in named studies; reasons included adherence problems, personal issues, injury and sickness, SARS-CoV-2 reinfection and fear of reinfection. Authors state no risk-of-bias and quality assessment was performed; they assume high risk of bias and low quality; heterogeneity was broad.
- Rehabilitation of Patients with Post-COVID-19 Syndrome: A Narrative Review.2023 · review
Summary
This narrative review asked whether rehabilitation helps people with post-COVID-19 condition. It searched PubMed and Web of Science to October 31, 2022, and included 10 articles; no overall number of participants enrolled or analysed was reported. The reviewed programs included pulmonary rehabilitation, physical exercise, respiratory muscle training, resistance and aerobic training, home-based inspiratory muscle training, tailored multicomponent exercise, and telerehabilitation. Comparisons were usual care, no treatment, WHO rehabilitation guidelines, self-management, or lower- versus higher-intensity aerobic training. Outcomes included FVC, 6MWD, HRQOL, dyspnea, QOL, functional capacity, and adverse events. Reina-Gutiérrez et al. reported predicted FVC increased by 5.5%, 6MWD by 44.55 m, and HRQOL by 3.9 points versus baseline. In McNarry et al. (281 participants), home-based IMT improved K-BILD breathlessness domains, Transition Dyspnea Index, respiratory muscle strength, and estimated aerobic fitness, but no between-group difference was found in K-BILD total score. Jimeno-Almazán et al. (39 participants) reported VO2 max +5.7%, sit-to-stand −22.7%, bench press +6.3%, and half squat +16.9% (P<0.05). Nambi et al. (76 participants) found improvement in both low- and high-intensity groups, with more improvement in the low-intensity group. Huang et al. reported telerehabilitation superiority for dyspnea, limb muscle strength, ambulation capacity, and depression, with no significant difference for anxiety or QOL. Vieira et al. (6 trials, 323 participants) reported improved 6MWDT, 30-s sit-to-stand, Dyspnea-12, and Borg scores. Ahmadi Hekmatikar et al. reported exercise without any adverse events or hospital re-admission, and the review stated no cases of worsening symptoms after rehabilitation.